Result of AGM

Evolutec Group PLC 04 May 2005 For immediate release 4 May 2005 EVOLUTEC GROUP PLC ('Evolutec' or 'the Company') Result of AGM Evolutec Group plc (AIM: EVC), a biopharmaceutical company developing novel products for the treatment of allergic, inflammatory and autoimmune diseases, is pleased to announce that all of the resolutions at the AGM of the Company, held today, were duly passed. David Bloxham, Evolutec's Chairman, commented: 'The Company is on track with its plans for the clinical development of rEV131, our lead compound. We are entering an exciting stage in the development of the Company and expect to deliver two Phase II clinical trial results by the end of 2005.' ENDS For further information: Evolutec 0118 922 4480 Mark Carnegie Brown, Chief Executive Officer Nicholas Badman, Chief Financial Officer www.evolutec.co.uk Collins Stewart 020 7523 8350 Chris Howard Buchanan Communications 020 7466 5000 Mark Court/Tim Anderson/Mary-Jane Johnson Notes for Editors: About Evolutec Evolutec, which is based in Reading, UK, is a clinical stage biopharmaceutical company with a focus on allergy, inflammation and auto-immune diseases. The Company has commenced a 112 patient proof of concept Phase II clinical trial with rEV131, its lead product, in allergic rhinitis. Evolutec intends to carry out additional proof of concept Phase II trials with rEV131 in post-cataract surgery and dry eye. Positive pre-clinical data has also been generated in asthma. rEV131 is a histamine binding protein and is understood to be the only product currently in clinical trials that impacts the recently discovered H4 receptor, a receptor implicated in many forms of inflammatory disease. The Company has a further two products in pre-clinical development: rEV598, which is being evaluated in carcinoid syndrome and CINV (chemotherapy-induced nausea and vomiting), and rEV576, a complement inhibitor. Evolutec was founded in 1998 to exploit research carried out by the Natural Environment Research Council. Evolutec's drugs were first isolated from the saliva of ticks. The tick remains undetected by its hosts, including humans, by injecting an array of molecules into the skin that suppresses normal defence mechanisms. These stealth molecules have evolved over millions of years to enable the tick to take a blood meal from its host. Evolutec employs the tick's evolutionary stealth technology to offer the potential of treating human diseases. Safe Harbour statement: this news release may contain forward-looking statements that reflect the current expectations of the Company regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion of clinical studies, the uncertainties related to the regulatory process, the successful integration of completed mergers and acquisitions and achievement of expected synergies from such transactions, and the ability of the Company to identify and consummate suitable strategic and business combination transactions. This information is provided by RNS The company news service from the London Stock Exchange
UK 100

Latest directors dealings